CO2021015622A2 - Combination therapies comprising apremilast and tyk2 inhibitors - Google Patents

Combination therapies comprising apremilast and tyk2 inhibitors

Info

Publication number
CO2021015622A2
CO2021015622A2 CONC2021/0015622A CO2021015622A CO2021015622A2 CO 2021015622 A2 CO2021015622 A2 CO 2021015622A2 CO 2021015622 A CO2021015622 A CO 2021015622A CO 2021015622 A2 CO2021015622 A2 CO 2021015622A2
Authority
CO
Colombia
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
CONC2021/0015622A
Other languages
Spanish (es)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CO2021015622A2 publication Critical patent/CO2021015622A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan en la presente métodos para tratar enfermedades y trastornos que responden a la inhibición de PDE4 que comprende administrar apremilast y un inhibidor de Tyk2 a un sujeto. También se proporcionan en la presente composiciones farmacéuticas que comprenden apremilast y un inhibidor de Tyk2.Provided herein are methods of treating diseases and disorders responsive to PDE4 inhibition comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.

CONC2021/0015622A 2019-04-30 2021-11-22 Combination therapies comprising apremilast and tyk2 inhibitors CO2021015622A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
PCT/US2020/030608 WO2020223431A1 (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
CO2021015622A2 true CO2021015622A2 (en) 2022-02-28

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2021/0015622A CO2021015622A2 (en) 2019-04-30 2021-11-22 Combination therapies comprising apremilast and tyk2 inhibitors
CONC2021/0015614A CO2021015614A2 (en) 2019-04-30 2021-11-22 Combination therapies comprising apremilast and tyk2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CONC2021/0015614A CO2021015614A2 (en) 2019-04-30 2021-11-22 Combination therapies comprising apremilast and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (2) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015622A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013317A (en) 2019-04-30 2022-01-18 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors.
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012149251A1 (en) * 2011-04-28 2012-11-01 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
SI2797581T1 (en) * 2011-12-27 2020-08-31 Amgen (Europe) GmbH Formulations of (+)-2-(1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl)-4-acetyl aminoisoindoline-1,3-dione
EP2802567B1 (en) 2012-01-10 2017-03-01 F. Hoffmann-La Roche AG Pyridazine amide compounds and their use as syk inhibitors
JPWO2013146963A1 (en) 2012-03-28 2015-12-14 武田薬品工業株式会社 Heterocyclic compounds
JP6197031B2 (en) 2012-05-24 2017-09-13 セルゾーム リミティッド Heterocyclyl pyrimidine analogs as TYK2 inhibitors
USRE47929E1 (en) 2012-11-08 2020-04-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
KR102205914B1 (en) * 2012-11-08 2021-01-20 브리스톨-마이어스 스큅 컴퍼니 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
CN105050624A (en) * 2013-03-14 2015-11-11 细胞基因公司 Treatment of psoriatic arthritis using apremilast
JPWO2015016206A1 (en) 2013-07-30 2017-03-02 武田薬品工業株式会社 Heterocyclic compounds
RU2652795C2 (en) 2013-09-03 2018-05-03 Сареум Лимитед 2-phenyl-oxazole-4-carboxamide derivatives, modulating activity of jak and tyk2 kinase
TWI582077B (en) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
MX2016014384A (en) * 2014-06-23 2017-01-20 Celgene Corp Apremilast for the treatment of a liver disease or a liver function abnormality.
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
EP3712153B1 (en) 2016-02-24 2021-12-01 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
US10836770B2 (en) 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018081488A1 (en) 2016-10-28 2018-05-03 Bristol-Myers Squibb Company Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
AU2018230737B2 (en) * 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
MX2021013317A (en) 2019-04-30 2022-01-18 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors.

Also Published As

Publication number Publication date
IL287670A (en) 2021-12-01
JP2022537878A (en) 2022-08-31
CN114206333A (en) 2022-03-18
CO2021015614A2 (en) 2021-12-10
JP2022537877A (en) 2022-08-31
CA3138686A1 (en) 2020-11-05
WO2020223431A1 (en) 2020-11-05
EP3962476A1 (en) 2022-03-09
BR112021021826A2 (en) 2022-01-04
IL287665A (en) 2022-07-01
KR20220002489A (en) 2022-01-06
CA3138473A1 (en) 2020-11-05
KR20220002488A (en) 2022-01-06
MX2021013318A (en) 2022-01-31
JP7453251B2 (en) 2024-03-19
SG11202112018YA (en) 2021-11-29
CL2021002847A1 (en) 2022-07-22
AU2020266143A1 (en) 2021-12-02
WO2020222773A1 (en) 2020-11-05
SG11202112043PA (en) 2021-11-29
BR112021021809A2 (en) 2022-01-04
CN114269336A (en) 2022-04-01
EP3962475A1 (en) 2022-03-09
AU2019443366A1 (en) 2021-12-02
MX2021013317A (en) 2022-01-18
BR112021021826A8 (en) 2022-06-21
MA55799A (en) 2022-03-09

Similar Documents

Publication Publication Date Title
CO2021015614A2 (en) Combination therapies comprising apremilast and tyk2 inhibitors
MX2018005600A (en) Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor.
CL2020002146A1 (en) N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer.
BR112018001640A2 (en) combination of pd-1 antagonist with an egfr inhibitor
BR112017013022A2 (en) methods for treating acute inflammatory and / or autoimmune disease in a mammal in need thereof where corticosteroid therapy is used as first or second line therapy and / or for treating an inflammatory and / or autoimmune disease in a mammal in need where corticosteroid therapy is required. Corticosteroid therapy is used as first or second line maintenance therapy and / or to eliminate or reduce therapeutic dose of corticosteroids used to treat an inflammatory and / or autoimmune disease in a mammal in need thereof, where corticosteroid therapy is used as first or second-line chronic maintenance therapy and / or treatment of an autoimmune and / or inflammatory disease in a mammal in need thereof
BR112015010477A2 (en) A pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases.
BR112016020199A8 (en) human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use
CR20220325A (en) Fluoroalkyl-oxadiazoles and uses thereof
BR112015026021A2 (en) combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA201790907A1 (en) NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS
ECSP22044525A (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
WO2018208793A8 (en) S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY.
EA201691555A1 (en) METHODS OF TREATMENT AND PREVENTION OF KIDNEY DISEASES AND LIVER FATIAL DYSTROPHIES
BR112022011892A2 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
BR112023000687A2 (en) METHODS AND COMBINATIONS OF KAT6 INHIBITORS FOR THE TREATMENT OF CANCER
BR112023015210A2 (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
CL2022001006A1 (en) tim-3 inhibitors and their uses
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
EA201990508A1 (en) ACTIVITY INHIBITION Olig2
AR116024A1 (en) METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
BR112022008580A2 (en) METHODS TO TREAT DEPRESSIVE DISORDERS
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
CL2021002846A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors